For EGFR amplification in IDH‐wildtype, the best and concordant models showed AUCs of 0.821 (95% CI: 0.761–0.881) and 0.746 (95% CI: 0.675–0.817) in newly diagnosed gliomas, but poor performance in recurrent tumors with AUCs of 0.503 (95% CI: 0.34–0.665) and 0.518 (95% CI: 0.357–0.678). Here, IDH2 is linked to central nervous system cancer.